Mernyák et al. reported that C16 α-estrone-triazole L3 (IC50 = 2.6–6.5 μM) could exert broad-spectrum antiproliferative activities against a panel of cancer cell lines including HeLa, MCF-7, A431, A2780, T47D (expressing androgen, progesterone and estrogen receptors), MDA-MB-231 (expressing HER2 and estrogen receptor) and triple-negative MDA-MB-361 (Mernyák et al., 2015), and it was comparable to or better than the reference drug cisplatin (IC50 = 1.3–19.1 μM). This evidence concerns the gene ESR1 and cancer.